Larimar Therapeutics, Inc. (LRMR)
NasdaqGM
Price as at 1 Oct 2026, 17:40 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Larimar Therapeutics, Inc. trades at $3.11. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
7 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$7.23M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$6.14M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$4.44M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$4.07M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$907.2K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own LRMR?
7 of the institutions we track reported a position in LRMR in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its LRMR data?
Fundamentals for LRMR come from company filings and exchange data, as listed on NasdaqGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 17:40 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for LRMR, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.